Korea Investment CORP Takes Position in IQVIA Holdings Inc. $IQV

Korea Investment CORP purchased a new position in shares of IQVIA Holdings Inc. (NYSE:IQV) in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor purchased 72,030 shares of the medical research company’s stock, valued at approximately $13,918,000.

A number of other institutional investors also recently bought and sold shares of the business. BlackRock Inc. acquired a new stake in IQVIA during the 2nd quarter worth approximately $2,811,292,000. Concurrent Investment Advisors LLC raised its stake in shares of IQVIA by 36.0% during the fourth quarter. Concurrent Investment Advisors LLC now owns 11,948 shares of the medical research company’s stock worth $2,693,000 after purchasing an additional 3,161 shares during the last quarter. Focus Partners Advisor Solutions LLC acquired a new stake in shares of IQVIA during the second quarter worth $976,000. Nippon Life Global Investors Americas Inc. grew its position in IQVIA by 36.6% in the 4th quarter. Nippon Life Global Investors Americas Inc. now owns 79,400 shares of the medical research company’s stock valued at $17,898,000 after buying an additional 21,270 shares during the last quarter. Finally, Munich Reinsurance Co Stock Corp in Munich acquired a new position in IQVIA in the 4th quarter valued at $3,444,000. 89.62% of the stock is currently owned by institutional investors and hedge funds.

IQVIA Stock Up 0.1%

IQV opened at $260.17 on Monday. The company has a debt-to-equity ratio of 2.18, a quick ratio of 0.71 and a current ratio of 0.71. The company has a market cap of $42.82 billion, a price-to-earnings ratio of 32.28, a PEG ratio of 2.21 and a beta of 1.18. IQVIA Holdings Inc. has a one year low of $154.50 and a one year high of $260.40. The business’s fifty day moving average is $213.32 and its two-hundred day moving average is $187.21.

IQVIA (NYSE:IQV) last released its quarterly earnings results on Tuesday, July 28th. The medical research company reported $3.15 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.03 by $0.12. The business had revenue of $4.37 billion during the quarter, compared to the consensus estimate of $4.30 billion. IQVIA had a return on equity of 30.25% and a net margin of 8.10%.The business’s revenue was up 8.7% on a year-over-year basis. During the same quarter in the previous year, the company posted $2.81 EPS. IQVIA has set its FY 2026 guidance at 12.800-13.000 EPS. Analysts anticipate that IQVIA Holdings Inc. will post 11.57 EPS for the current fiscal year.

IQVIA announced that its board has approved a stock buyback program on Thursday, May 7th that permits the company to repurchase $2.00 billion in shares. This repurchase authorization permits the medical research company to repurchase up to 6.8% of its shares through open market purchases. Shares repurchase programs are often a sign that the company’s board believes its shares are undervalued.

Analyst Ratings Changes

Several analysts have recently commented on the stock. Morgan Stanley restated an “equal weight” rating and issued a $200.00 target price (down from $225.00) on shares of IQVIA in a research note on Wednesday, June 17th. BMO Capital Markets increased their price target on shares of IQVIA from $210.00 to $270.00 and gave the stock an “outperform” rating in a report on Wednesday, July 29th. Deutsche Bank Aktiengesellschaft set a $240.00 price objective on shares of IQVIA in a research report on Thursday, July 9th. JPMorgan Chase & Co. boosted their target price on IQVIA from $225.00 to $285.00 and gave the stock an “overweight” rating in a research report on Wednesday, July 29th. Finally, Robert W. Baird increased their target price on IQVIA from $252.00 to $287.00 and gave the stock an “outperform” rating in a research note on Wednesday, July 29th. One research analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating and three have given a Hold rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $241.88.

Insider Buying and Selling at IQVIA

In other news, insider Eric Sherbet sold 5,000 shares of the company’s stock in a transaction on Wednesday, July 29th. The stock was sold at an average price of $249.16, for a total value of $1,245,800.00. Following the sale, the insider directly owned 20,999 shares in the company, valued at $5,232,110.84. This represents a 19.23% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Keriann Cherofsky sold 558 shares of IQVIA stock in a transaction dated Wednesday, July 29th. The stock was sold at an average price of $245.21, for a total value of $136,827.18. Following the sale, the insider owned 2,989 shares of the company’s stock, valued at approximately $732,932.69. This represents a 15.73% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold 12,913 shares of company stock valued at $3,098,793 over the last three months. Company insiders own 1.70% of the company’s stock.

IQVIA Company Profile

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real?world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real?world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.